Walleye Trading’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$45.2M Buy
1,231,000
+234,500
+24% +$11.1M 0.08% 261
2025
Q4
$50.7M Buy
996,500
+101,900
+11% +$5.21M 0.07% 287
2025
Q3
$49.6M Buy
894,600
+567,700
+174% +$33.2M 0.08% 266
2025
Q2
$22.6M Buy
326,900
+34,900
+12% +$2.37M 0.04% 478
2025
Q1
$20.3M Buy
292,000
+147,200
+102% +$12.2M 0.05% 441
2024
Q4
$12.5M Sell
144,800
-129,000
-47% -$13.9M 0.03% 675
2024
Q3
$32.6M Buy
273,800
+178,900
+189% +$23.9M 0.07% 299
2024
Q2
$13.5M Sell
94,900
-31,200
-25% -$4.13M 0.03% 543
2024
Q1
$16.2M Sell
126,100
-67,600
-35% -$8.05M 0.03% 498
2023
Q4
$20M Sell
193,700
-97,400
-33% -$9.63M 0.04% 442
2023
Q3
$26.5M Sell
291,100
-147,700
-34% -$13M 0.07% 281
2023
Q2
$35.5M Buy
438,800
+271,000
+162% +$22.1M 0.11% 168
2023
Q1
$13.4M Buy
167,800
+79,800
+91% +$5.66M 0.03% 513
2022
Q4
$5.95M Sell
88,000
-126,400
-59% -$7.41M 0.02% 958
2022
Q3
$10.7M Buy
214,400
+57,400
+37% +$3.07M 0.03% 595
2022
Q2
$8.75M Buy
157,000
+137,400
+701% +$7.62M 0.03% 699
2022
Q1
$1.09M Sell
19,600
-22,800
-54% -$1.17M ﹤0.01% 2154
2021
Q4
$2.37M Sell
42,400
-3,600
-8% -$195K 0.01% 1484
2021
Q3
$2.21M Buy
+46,000
New +$2.22M 0.01% 1532
2021
Q2
Sell
-5,200
Closed -$175K 5422
2021
Q1
$175K Sell
5,200
-6,400
-55% -$228K ﹤0.01% 3739
2020
Q4
$405K Sell
11,600
-10,000
-46% -$346K ﹤0.01% 2864
2020
Q3
$750K Sell
21,600
-51,800
-71% -$1.73M ﹤0.01% 1890
2020
Q2
$2.4M Buy
73,400
+59,200
+417% +$1.89M 0.02% 959
2020
Q1
$427K Sell
14,200
-76,200
-84% -$2.27M ﹤0.01% 1984
2019
Q4
$2.62M Buy
90,400
+34,800
+63% +$964K 0.02% 1005
2019
Q3
$1.44M Sell
55,600
-1,000
-2% -$25.3K 0.01% 1327
2019
Q2
$1.44M Sell
56,600
-72,000
-56% -$1.78M 0.01% 1298
2019
Q1
$3.36M Sell
128,600
-81,000
-39% -$1.99M 0.03% 719
2018
Q4
$4.83M Sell
209,600
-68,000
-24% -$1.51M 0.04% 495
2018
Q3
$6.54M Buy
277,600
+117,000
+73% +$2.86M 0.03% 502
2018
Q2
$3.7M Buy
160,600
+135,200
+532% +$3.21M 0.02% 816
2018
Q1
$625K Sell
25,400
-19,200
-43% -$504K ﹤0.01% 2421
2017
Q4
$1.2K Sell
44,600
-1,000
-2% -$25.4K 0.01% 1757
2017
Q3
$1.1K Buy
45,600
+17,400
+62% +$393K 0.01% 1800
2017
Q2
$605 Sell
28,200
-51,800
-65% -$1.05M ﹤0.01% 2206
2017
Q1
$1.37K Buy
80,000
+42,200
+112% +$735K 0.01% 1381
2016
Q4
$678K Sell
37,800
-19,400
-34% -$352K ﹤0.01% 1827
2016
Q3
$1.19M Buy
57,200
+42,200
+281% +$1.05M 0.01% 1394
2016
Q2
$403K Sell
15,000
-34,200
-70% -$938K ﹤0.01% 2404
2016
Q1
$1.33M Buy
49,200
+15,400
+46% +$413K 0.01% 1151
2015
Q4
$982K Buy
33,800
+31,400
+1,308% +$869K 0.01% 1272
2015
Q3
$65K Buy
2,400
+200
+9% +$5.66K ﹤0.01% 3311
2015
Q2
$60K Sell
2,200
-2,400
-52% -$67.5K ﹤0.01% 3384
2015
Q1
$123K Sell
4,600
-600
-12% -$13.8K ﹤0.01% 2535
2014
Q4
$110K Buy
5,200
+5,000
+2,500% +$112K ﹤0.01% 2737
2014
Q3
$5K Sell
200
-1,000
-83% -$23K ﹤0.01% 3899
2014
Q2
$28 Sell
1,200
-6,000
-83% -$132K ﹤0.01% 3120
2014
Q1
$165 Buy
7,200
+4,200
+140% +$89.5K ﹤0.01% 2056
2013
Q4
$54K Buy
+3,000
New +$52.3K ﹤0.01% 2795

Other funds holding NVO

Walleye Trading's NVO Position: Q1 2026 in Review

Walleye Trading increased its Novo Nordisk (NVO) stake by 11% in Q1 2026, buying an estimated $1.71M and bringing the position to 378,650 shares worth $13.9M. The position accounts for 0.02% of the portfolio, ranked #643.

Walleye Trading first reported a position in NVO in Q2 2013 and has held it in 26 quarters since. The position peaked at $52.5M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Walleye Trading held 378,650 shares of Novo Nordisk worth $13.9M as of Q1 2026.
  • Walleye Trading bought 36,143 Novo Nordisk shares in Q1 2026, an estimated $1.71M.
  • Novo Nordisk made up 0.02% of Walleye Trading's portfolio in Q1 2026, its #643 holding.
  • Walleye Trading first reported a position in Novo Nordisk in Q2 2013 and has held it in 26 quarters since.
  • Walleye Trading's Novo Nordisk position peaked at $52.5M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.